Main / Arcade / Stargardts disease clinical trials
Stargardts disease clinical trials
Stargardt's Disease, Drug: SAR, Phase 1 Phase 2 Diagnosis of Stargardt's Macular Degeneration (SMD), with at least one pathogenic mutant ABCA4. Male or female between 12 and 60 years old (inclusive), with any visual acuity. Has a clinical diagnosis of typical autosomal recessive Stargardt macular dystrophy (STGD1) Has provided a genetic report indicating at least two ABCA4 disease-causing mutations. Saffron Supplementation in Stargardt's Disease (STARSAF02) Brief Summary: The general area of research in which this project has been designed is that of retinal degeneration related to mutations in the ABCR gene, responsible of Stargardt disease/fundus flavimaculatus retinal dystrophy (STD/FF).
Description: The Catholic University of the Sacred Heart in Italy is conducting a person clinical trial of saffron for the treatment of Stargardt disease. Saffron supplementation has inhibited retinal degeneration in lab studies.
News and research related to the ProgStar Study of Stargardt Disease (STGD), in future clinical trials for Stargardt disease and other macular diseases. The randomized, double-masked, sham-controlled clinical trial will phase 2b trial of Zimura for the treatment of autosomal recessive Stargardt.
ONGOING CLINICAL TRIALS. Stargardt Disease: Phase 2 Clinical Trial Enrolling Participants 12 years and older in the USA. We are currently enrolling patients. Stargardt disease is an inherited disorder of the retina – the tissue at the The eyeGENE network gives patients access to genetic studies and clinical trials. Ocata's most advanced products are in clinical trials for the treatment of dry age- related macular degeneration, Stargardt disease, and myopic.
Stargardt disease: clinical features, molecular genetics, animal models and with human clinical trials of stem cell therapy, gene replacement therapy and.
В© 2018 switoutneudi.host